Complex analysis of the personalized pharmacotherapy in the management of COVID-19 patients and suggestions for applications of predictive, preventive, and personalized medicine attitude.

Wang, Lei-Yun; Cui, Jia-Jia; OuYang, Qian-Ying; Zhan, Yan; Wang, Yi-Min; Xu, Xiang-Yang; Yu, Lu-Lu; Yin, Hui; Wang, Yang; Luo, Chen-Hui; Guo, Cheng-Xian; Yin, Ji-Ye

Wang, Lei-Yun; Cui, Jia-Jia; OuYang, Qian-Ying; Zhan, Yan; Wang, Yi-Min; Xu, Xiang-Yang; Yu, Lu-Lu; Yin, Hui; Wang, Yang; Luo, Chen-Hui; Guo, Cheng-Xian; Yin, Ji-Ye.

Afiliação

Wang LY; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410078 Hunan People's Republic of China.
Cui JJ; Institute of Clinical Pharmacology, Central South University, Changsha, China.
OuYang QY; Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078 Hunan People's Republic of China.
Zhan Y; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha, 410078 Hunan People's Republic of China.
Wang YM; National Clinical Research Center for Geriatric Disorders, 87 Xiangya Road, Changsha, 410008 Hunan People's Republic of China.
Xu XY; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410078 Hunan People's Republic of China.
Yu LL; Institute of Clinical Pharmacology, Central South University, Changsha, China.
Yin H; Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078 Hunan People's Republic of China.
Wang Y; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha, 410078 Hunan People's Republic of China.
Luo CH; National Clinical Research Center for Geriatric Disorders, 87 Xiangya Road, Changsha, 410008 Hunan People's Republic of China.
Guo CX; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410078 Hunan People's Republic of China.
Yin JY; Institute of Clinical Pharmacology, Central South University, Changsha, China.

EPMA J ; 12(3): 307-324, 2021 Sep.

Article em En | MEDLINE | ID: mdl-34306260

Palavras-chave

COVID-19; Ceftriaxone; Chloroquine; Comorbidities; Daclatasvir; Dexamethasone; Drug score; Drug-to-drug interaction; Ethnicity-based differences; Future healthcare; Gene score; HCQ; Human immunoglobulin G; Hydroxychloroquine; Individual outcomes; Interferon alpha-2b; Interferon beta-1a; Levofloxacin; Lopinavir; Losartan; Molecular mechanisms; Optimal medication; Personalized treatment; Pharmacogenetics; Pharmacogenomics; Predictive preventive personalized medicine (PPPM/3 PM); Prednisone; Remdesivir; Ribavirin; Ritonavir; Sofosbuvir; Zinc

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: EPMA J Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google